



ABN 53 075 582 740

ASX ANNOUNCEMENT

24 May 2017

Bionomics Recruits International Executive as CFO

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, today announced the appointment of Steve Lydeamore as its Chief Financial Officer (CFO), commencing in August 2017.

Mr. Lydeamore is a Certified Practising Accountant with 25 years' international pharmaceutical experience. He has a B.Bus. (Appl. Ec.) from Deakin University and an MBA from RMIT University. Mr. Lydeamore worked in various finance roles for F.H. Faulding & Co. Limited in Australia over a ten year period followed by four years in the United States at Mayne Pharma (USA) Limited. For the last eleven years Mr. Lydeamore has worked for Apotex Inc., Canada's largest pharmaceutical company, most recently as President, Apobiologix which is pioneering development of biosimilar oncology treatments. Mr Lydeamore will be relocating to Adelaide with his family to take up this appointment.

Bionomics' CEO & Managing Director, Dr Deborah Rathjen, said, "I am very pleased to have someone of Steve's experience and expertise join the Bionomics team. His experience not only in finance but in international business development and partnering is highly relevant to Bionomics and Steve will be a great addition to our team. I look forward to working closely with him when he joins Bionomics in August".

Mr Lydeamore commented "I am passionate about developing treatment options for debilitating and life-threatening diseases and I am very much looking forward to joining Bionomics at this exciting time".

Ms Melanie Young has resigned as CFO and Mr. Stephen Birrell has been appointed interim-CFO until Mr Lydeamore takes up his position. Mr. Birrell was Bionomics' CFO from 2005-2009 and rejoined Bionomics in 2013 as Group Financial Controller. The Board expresses its appreciation to Ms. Young for her service and wishes her well with future endeavours.

FOR FURTHER INFORMATION PLEASE CONTACT:

Deborah Rathjen
CEO & Managing Director
Bionomics Limited
+61883546101

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.